[Oncogenicity of gamma-(1-methyl-5-bis-(beta-chloroethyl)-aminobenzimidazolyl-(2))-butyric acid hydrochloride (cytostasan) in mice (author's transl)].
D000236:Adenoma / Q000139:chemically induced; D000284:Administration, Oral; D000818:Animals; D001562:Benzimidazoles; D002273:Carcinogens; D004305:Dose-Response Relationship, Drug; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced; D007274:Injections, Intraperitoneal; D008175:Lung Neoplasms / Q000139:chemically induced; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced; D051379:Mice; D008805:Mice, Inbred A; D009374:Neoplasms, Experimental / Q000139:chemically induced; D009588:Nitrogen Mustard Compounds; D010538:Peritonitis / Q000139:chemically induced; D013997:Time Factors; D014611:Vaccination
D001562:Benzimidazoles; D002273:Carcinogens; D009588:Nitrogen Mustard Compounds
Onkogene Wirkung von gamma-(1-Methyl-5-bis-(beta-chloräthyl)-aminobenzimidazoly-(2))-buttersäurehydrochlorid (Cytostasan) bei der Maus